Framingham, MA, United States of America

Lynn Doucette-Stamm

This inventor holds 59 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Cardiovascular Treatments (CPC class C12Q). Top assignees: Sanofi Pasteur Inc., Sanofi Pasteur Limited/sanofi Pasteur Limitee, Wyeth. Active years: 2002-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lynn Doucette-Stamm. Retrieved from https://idiyas.com/inventor/lynn-doucette-stamm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 59 

% Patents Active = 16.9

 

Average Co-Inventor Count = 3.8

ph-index = 18

Forward Citations = 983(Granted Patents)

Forward Citations (Not Self Cited) = 452(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 2002-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
Cardiovascular Disease
Treatment Methods
Response Prediction
Kits
Medical Devices
Health Monitoring
Patient Care
Disease Management
Clinical Applications
Therapeutic Strategies
Diagnostic Tools
Innovative Solutions
59 patents (USPTO):Explore Patents

Title: Lynn Doucette-Stamm: Innovator in Cardiovascular Treatment

Introduction

Lynn Doucette-Stamm, based in Framingham, MA, is a prolific inventor with a remarkable portfolio of 59 patents. His work primarily focuses on innovative methods and kits aimed at treating cardiovascular diseases, showcasing his commitment to improving healthcare through scientific advancements.

Latest Patents

Among his latest patents, two stand out significantly. The first patent addresses "Methods and kits for treating cardiovascular disease," where Lynn has developed novel approaches to aid in the management of heart-related conditions. The second patent is titled "Methods for predicting response to treatment." This invention provides critical stratification methods and kits to identify individuals with inflammation-related disorders based on their genotype-specific expression of IL-1. By discerning whether a patient is a 'high' or 'low' producer of IL-1, this invention enables healthcare providers to prescribe appropriate anti-inflammatory drugs and dosages, ultimately minimizing drug toxicity and adverse effects—helping clinicians make better-informed decisions for individual patients.

Career Highlights

Lynn has had a notable career, having worked with leading organizations in the pharmaceutical sector, including Sanofi Pasteur Inc. and Sanofi Pasteur Limited. His experience at these esteemed companies has provided him with the platform to further his innovations in medical treatments and applications.

Collaborations

Throughout his career, Lynn has collaborated with accomplished professionals such as David E. Bush and Timothy Opperman. These partnerships have fostered an environment of shared ideas and collective advancement in the field of medical technology and treatments.

Conclusion

Lynn Doucette-Stamm exemplifies the spirit of innovation in healthcare. With his extensive portfolio of patents and collaborations, he has made significant contributions to the treatment of cardiovascular diseases and the prediction of patient responses to treatments. His work continues to inspire new advancements in medical science, reflecting a dedication to improving patient care through innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…